Apellis Pharmaceuticals is currently testing the bottom of a key weekly gap near the $20 level, an area that has historically acted as a strong support zone. A confirmed breakout above the $29 level would signal renewed bullish momentum and open the path toward the $35.25 resistance, which aligns with prior supply and structural resistance.
APLS looks primed for a bounce as selling pressure fades and momentum indicators begin to shift upward. With a clearly defined stop-loss at $18.50, this setup offers a strong risk-to-reward profile, giving traders controlled downside and meaningful upside potential.
Fundamentally, positive sentiment continues around Apellis’ commercial rollout of Syfovre and its expanding pipeline in complement inhibition—adding further tailwind to the technical setup.
APLS looks primed for a bounce as selling pressure fades and momentum indicators begin to shift upward. With a clearly defined stop-loss at $18.50, this setup offers a strong risk-to-reward profile, giving traders controlled downside and meaningful upside potential.
Fundamentally, positive sentiment continues around Apellis’ commercial rollout of Syfovre and its expanding pipeline in complement inhibition—adding further tailwind to the technical setup.
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。